Placeholder Banner

BIO Industry Analysis Reports

Download past BIO Industry Analysis reports, and sign up to be notified of upcoming reports.

IRA’s Impact on the Biopharma Ecosystem
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas.
Slides from BIO 2023 – The State of Emerging Biotech

Download slides from #BIO2023 on the state of emerging therapeutic companies. 

The State of Innovation in Antibacterial Therapeutics

This report investigates recent investment into antibacterial innovation and the current clinical pipeline that will help bridge the gaps in the antibacterial armamentarium.

Sign up to request future reports from BIO Industry Analysis:

The State of Innovation in Pain and Addiction February 2023

New Report

This report by BIO’s Industry Analysis team examines recent investment trends in pain and addiction innovation and the current clinical pipeline for new therapeutics.

Emerging Therapeutic Company Investment and Deal Trends

New BIO Industry Analysis trend data have been released for Emerging Therapeutic Company Investment, R&D-Stage Out-licensing, and Acquisitions.

COVID-19 Therapeutic Development Tracker

BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create an interactive view of the COVID-19 pipeline. New data released every Monday!

FDA Approvals & Clinical Development Pipeline

BIO’s Industry Analysis Team presents FDA Approval Trends that are filterable by various attributes including: size of company, molecule size, disease area, and various expedited approval pathways. 

Available Reports:

Latest Report: Clinical Development Success Rates 2011-2020

BIO, QLS Advisors, and Informa Pharma Intelligence have released a new report on clinical development success rates covering 2011-2020.